NCT02251223View on ClinicalTrials.gov

Effects of Tipranavir/Ritonavir on the Pharmacokinetic Characteristics of Triple Drug Nucleoside and Non-nucleoside Reverse Transcriptase Inhibitor Therapy in HIV-1-infected Subjects

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

208

Participants

Timeline

Start Date

February 28, 2001

Primary Completion Date

February 28, 2002

Conditions
HIV Infections
Interventions
DRUG

Tipranavir low dose

DRUG

Tipranavir medium dose

DRUG

Tipranavir high dose

DRUG

Ritonavir low dose

DRUG

Ritonavir high dose

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT02251223 - Effects of Tipranavir/Ritonavir on the Pharmacokinetic Characteristics of Triple Drug Nucleoside and Non-nucleoside Reverse Transcriptase Inhibitor Therapy in HIV-1-infected Subjects | Biotech Hunter | Biotech Hunter